SubsidieMeestersNovel small molecule attenuator of neuroinflammation in Parkinson’s Disease
NEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap.
Projectdetails
Introduction
Parkinson’s disease (PD) affects 8.5 million individuals worldwide according to WHO estimates. PD remains cureless and treatments are based on the administration of dopamine precursors or analogues.
Neuroinflammation in PD
Neuroinflammation is a central hallmark of PD; however, no molecule is present in the market to tackle neuroinflammation in PD patients. Neuroinflammation contributes to the exacerbation of the disease, as the release of inflammatory signals leads to reduced neuronal fitness, driving neuronal death.
NEUROSHIELD's Objective
NEUROSHIELD will address this gap in PD treatment to ensure an increased quality of life for PD patients while exploiting this therapeutic market opportunity.
Limitations of Current Treatments
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in PD has been considered non-effective or has raised long-term usage complications due to adverse side effects.
Novel Approach
NEUROSHIELD will employ a novel small molecule tackling neuroinflammation through a yet unexplored pathway, which is a different mechanism from the classic NSAID COX-2 inhibitors. We have identified a novel potent first-in-class small molecule that is a strong attenuator of neuroinflammation.
Goals of NEUROSHIELD
NEUROSHIELD aims to explore this new safe, brain-permeable molecule, addressing neuroinflammation in Parkinson’s disease through a novel pathway.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-2-2025 |
| Einddatum | 31-7-2026 |
| Subsidiejaar | 2025 |
Partners & Locaties
Projectpartners
- UNIVERSIDADE NOVA DE LISBOApenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's DiseaseThe NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models. | ERC Proof of... | € 150.000 | 2022 | Details |
Unraveling Parkinson´s disease diagnosticUNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden. | ERC Proof of... | € 150.000 | 2024 | Details |
Probing (Orphan) Nuclear Receptors in NeurodegenerationNeuRoPROBE aims to develop chemical probes and PROTACs for orphan nuclear receptors TLX and Nurr1 using AI to advance therapeutic strategies against neurodegenerative diseases. | ERC Starting... | € 1.498.813 | 2022 | Details |
Chronic PAIN eradiCAtion by taRgeting Schwann cEllsPAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
Repurposing a human drug to treat Alzheimer’s diseaseThis project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease. | ERC Proof of... | € 150.000 | 2022 | Details |
Targetting neutrophil-mediated neurotoxicity for the treatment of Alzheimer's Disease
The NeutrAD project aims to develop and commercialize the first disease-modifying Alzheimer's drugs targeting neutrophil-mediated neurotoxicity, with promising results in preclinical models.
Unraveling Parkinson´s disease diagnostic
UNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden.
Probing (Orphan) Nuclear Receptors in Neurodegeneration
NeuRoPROBE aims to develop chemical probes and PROTACs for orphan nuclear receptors TLX and Nurr1 using AI to advance therapeutic strategies against neurodegenerative diseases.
Chronic PAIN eradiCAtion by taRgeting Schwann cElls
PAIN-CARE aims to develop Schwann cell selective analgesic drugs to effectively treat chronic pain with fewer side effects than current NSAIDs and opioids, advancing towards pre-commercialization.
Repurposing a human drug to treat Alzheimer’s disease
This project aims to validate an approved drug that inhibits tau accumulation in Alzheimer's, advancing it towards commercialization as a novel treatment for the disease.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions. | EIC Accelerator | € 1.636.639 | 2024 | Details |
Revolutionary therapeutic treatment for stopping progression of Parkinson's diseaseHerantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Antilichaam voor Parkison behandelingAugmentor Management ontwikkelt een specifiek antilichaam tegen alphasynucleine oligomeren om de progressie van de ziekte van Parkinson te remmen en zoekt haalbaarheid voor verder onderzoek. | Mkb-innovati... | € 20.000 | 2021 | Details |
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative DiseaseThe project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens. | EIC Pathfinder | € 2.992.203 | 2022 | Details |
PN6047 - a breakthrough treatment of neuropathic painPharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development. | EIC Accelerator | € 2.493.000 | 2024 | Details |
Developing a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF)
GeneCode is developing an oral anti-PD drug that mimics GDNF peptide pathways to restore dopamine neurons and alleviate symptoms in Parkinson's patients, with potential applications for other conditions.
Revolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Antilichaam voor Parkison behandeling
Augmentor Management ontwikkelt een specifiek antilichaam tegen alphasynucleine oligomeren om de progressie van de ziekte van Parkinson te remmen en zoekt haalbaarheid voor verder onderzoek.
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
PN6047 - a breakthrough treatment of neuropathic pain
PharmNovo aims to advance PN6047, a selective delta opioid receptor agonist for neuropathic pain, through Phase IIa trials to confirm efficacy and attract investment for further development.